DPP4 and obesity due to melanocortin 4 receptor deficiency: Thus, it is intriguing to test in the future whether EA could be potentially a more effective anti-diabetic and anti-obesity agent than some of the currently prescribed monotherapeutic drugs such as DPP4 inhibitors, metformin, and GLP-1 analogs.